In Brief: Elscint, Inc.
This article was originally published in The Gray Sheet
Elscint, Inc.: Thomas Spackman, MD, resigns as president and CEO of the Hackensack, New Jersey-based Elscint Ltd. subsidiary, a position he has held since December 1993. Spackman will continue to serve on the firm's board of directors. Peter Annand is promoted to COO from senior-VP of operations, and Sandra Serrett-Curran is promoted to senior-VP from VP of finance, pending board approval. Annand and Serrett-Curran will oversee the duties previously handled by Spackman. "A decision will be made later in 1997 as to whether Elscint will appoint a new president and CEO," the firm says...
You may also be interested in...
After urging the US Congress to act on updating Medicare Part D, the Association for Accessible Medicines has welcomed the decision to update Part D by the Centers for Medicare & Medicaid Services of the US Department of Health and Human Services.
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.
“You can’t just live off the brand equity anymore,” warned J&J's Consumer Health's Minoj Raghunandanan during the ‘Advancing Trust in the Self-Care Industry’ webinar co-hosted by the Global Self-Care Federation and HBW Insight. “You’ve got to continue to build that trust between consumers and products day-in day-out.”